Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135642 | 1.00 | SLC6A3 (0.42) | SLC6A3SLC6A4CHRNA7HTTMEN1 | |
| SCHEMBL4151625 | 0.88 | SLC6A3 (0.35) | SLC6A3SLC6A4 | |
| SCHEMBL4145963 | 0.81 | SLC6A3 (0.46) | SLC6A3SLC6A4 | |
| SCHEMBL4516283 | 0.80 | SLC6A3 (0.39) | SLC6A3SLC6A4 | |
| SCHEMBL4516285 | 0.80 | SLC6A3 (0.39) | SLC6A3SLC6A4 | |
| SCHEMBL4520081 | 0.80 | SLC6A3 (0.39) | SLC6A3SLC6A4 | |
| SCHEMBL3421449 | 0.77 | SLC6A3 (0.39) | SLC6A3SLC6A4CHRNA7 | |
| SCHEMBL4135078 | 0.77 | SLC6A3 (0.39) | SLC6A3SLC6A4CHRNA7 | |
| SCHEMBL4144769 | 0.74 | SLC6A3 (0.44) | SLC6A3SLC6A4CHRNA7HTTMEN1 | |
| SCHEMBL4147555 | 0.74 | SLC6A3 (0.44) | SLC6A3SLC6A4CHRNA7HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090208415-A1 | Tropane compounds | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208415-A1 | Tropane compounds | TPM3, TPM4, ADRA2C | SLC6A3 196/4885SLC6A4 217/4885CHRNA7 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.